LAIR1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue lysate, Primary antibody: P07415(LAIR1 Antibody) at dilution 1/1300, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07415(LAIR1 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07415(LAIR1 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), also known as CD305. is an inhibitory immune checkpoint receptor belonging to the immunoglobulin superfamily. Expressed broadly on immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells, LAIR1 contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases to dampen cellular activation signals. It binds collagen and collagen-like molecules, serving as a sensor for extracellular matrix (ECM) components. This interaction plays a role in maintaining immune homeostasis by suppressing excessive immune responses, particularly in contexts of tissue remodeling or damage.

LAIR1’s immunosuppressive function has dual implications in disease. In cancer, tumor-derived collagen or LAIR1 ligands in the microenvironment may engage LAIR1 to evade immune surveillance, promoting tolerance. Conversely, in autoimmune disorders, excessive LAIR1 signaling might contribute to immune suppression, limiting pathogenic responses. LAIR1-targeting antibodies are being explored therapeutically: blocking antibodies aim to disrupt inhibitory signaling in cancers, potentially enhancing antitumor immunity, while agonist antibodies could suppress hyperactive immune cells in autoimmunity.

Recent studies also highlight LAIR1’s role in regulating memory T cells and its crosstalk with other checkpoints like PD-1. Preclinical models demonstrate that LAIR1 blockade synergizes with existing immunotherapies, underscoring its potential as a novel target. However, balancing therapeutic efficacy with autoimmune risks remains a critical challenge in development.